Cetrorelix Acetate for Injection Product
Ganirelix Acetate Injection suppresses premature luteinizing hormone surges during fertility treatments.

Hybio Pharmaceutical develops, manufactures, and markets peptide and oligonucleotide drugs.
hybio.comCrawled Nov 15, 2026
Ganirelix Acetate Injection suppresses premature luteinizing hormone surges during fertility treatments.
Oxytocin Injection supports medical treatments for professionals and patients.
Atosiban Acetate Injection manages preterm labor for expectant mothers.
Carbetocin Injection manages uterine contractions for postpartum care.
Desmopressin Injection treats bedwetting in children and adults.
Somatostatin injection manages hormone-related disorders.
Hybio Pharmaceutical Co., Ltd. offers CE-certified medications, including Mounjaro, for businesses.
Hybio Pharmaceutical Co., Ltd. supplies Mounjaro similar drugs from trusted manufacturers.
As a B2B purchaser, I appreciate high-quality Ozempic similar drugs from trusted suppliers and manufacturers like Hybio Pharmaceutical Co., Ltd
Hybio Pharmaceutical Co., Ltd. provides GMP-compliant manufacturing and supply services for businesses.
Hybio Pharmaceutical Co., Ltd. supplies cleanroom technology solutions for manufacturers.
Hybio Pharmaceutical Co., Ltd. offers CE-certified Quality Assurance services, connecting suppliers and manufacturers.
Hybio Pharmaceutical Co., Ltd. provides R&D solutions as a trusted supplier and manufacturer.
Hybio Pharmaceutical Co., Ltd. specializes in Scale-Up Production for manufacturers and suppliers.
Hybio is a enterprise in the research, production of peptide pharmaceuticals. Main products include peptide raw materials, peptide skincare products.
Hybio Pharmaceutical Co., Ltd.’s Pingshan Branch completes a U.S. FDA on-site inspection for drug-device combination products with no deficiencies (NAI). The inspection, part of a specialized FDA review, covers stricter regulatory criteria than standard pharmaceutical checks. This marks the third successful inspection for the branch under this program.
Hybio Pharmaceutical secures NMPA approval for its HY3003 oral tablets to advance into clinical trials. The company expands its pipeline by accelerating development of multiple dosage forms for its triple agonist drug candidate. This follows rapid regulatory progress for the product.
Hybio Pharmaceutical secures U.S. FDA approval for its **HY3003 Injection** (IND No. 184763) to proceed with a **first-in-human clinical trial**. The drug passes the FDA’s safety review, enabling the company to advance testing under the submitted protocol. This marks a key milestone for Hybio’s pipeline of innovative pharmaceutical products.
HYBIO Pharmaceutical becomes the first Chinese company to submit a domestic marketing application for its tirzepatide injection to China’s National Medical Products Administration (NMPA). The approval accelerates the company’s global commercial strategy, with simultaneous filings underway in China and the U.S. Tirzepatide, a self-developed drug, represents a key step toward local production and market access for HYBIO Pharmaceutical.
Hybio Pharmaceutical secures China’s first approval for synthetic liraglutide, covering both active pharmaceutical ingredient (API) and finished dosage form (FDF) production. The company now controls the entire industrial chain for GLP-1 metabolic drugs, reinforcing its competitive barriers in this therapeutic area. This breakthrough positions Hybio as a key player in China’s GLP-1 drug development ecosystem.
Hybio Pharmaceutical and Sunshine Mandi Pharmaceutical jointly submitted a New Drug Application (NDA) for Hybio’s independently developed **Semaglutide Injection** for **long-term weight management**. The **China National Medical Products Administration (NMPA)**’s **Center for Drug Evaluation (CDE)** formally accepted the filing. The drug targets metabolic health through a GLP-1 receptor agonist mechanism, aligning with rising demand for obesity treatments in China.
Hybio Pharmaceutical licenses its **Liraglutide** and **Semaglutide** injections to **MCG Pharma** to enter the Turkish market. The agreement, signed April 10, 2026, expands Hybio’s international reach by partnering with a leading Turkish pharmaceutical company. Both drugs are now available in Turkey under the collaboration.
Hybio Pharmaceutical secures U.S. FDA approval for its self-developed **Glatiramer Acetate Injection**, a peptide-based therapy for **multiple sclerosis (MS)**. This marks the company’s second high-complexity peptide product approved in the U.S., following its **Liraglutide injection**. The approval advances Hybio’s global expansion strategy in specialized peptide therapeutics.